Kiora Pharmaceuticals, Inc. (KPRX) Q1 2024 Earnings
KPRX·Reported May 10, 2024·Before market open
Kiora Pharmaceuticals, Inc. reported Q1 2024 revenue of $16.0M. Diluted EPS came in at $3.42, missed the $5.58 consensus by $2.16.
Revenue
$16.0Mmet estimate
Consensus: $16.0MDiluted EPS
$3.42missed by $2.16
Consensus: $5.58
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Kiora Pharmaceuticals, Inc.'s Q1 2024 earnings report.
Kiora Pharmaceuticals, Inc. (KPRX) reported Q1 2024 earnings on May 10, 2024 before market open.
Kiora Pharmaceuticals, Inc. reported revenue of $16.0M and diluted EPS of $3.42 for Q1 2024.
Revenue beat the consensus estimate of $16.0M by -. EPS missed the consensus estimate of $5.58 by $2.16.
You can read the 10-Q periodic report (0001372514-24-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.